Forcyte Biotechnologies
Discover drugs that control how much cells squeeze to treat disease
- Founded
- 2017
- Status
- Inactive
- Stage
- Early
- Team size
- 5
- Location
- Los Angeles, CA, USA
- Category
- Biotech & Drug Discovery
- Sector
- Diagnostics
About Forcyte Biotechnologies
In a nutshell: many diseases are caused by how much your cells squeeze (asthma, fibrosis, others). We discover drugs that control how much cells squeeze, with ease, to treat disease. We use patented bioMEMS technology to turn cell strength (cells' ability to pull/ squeeze) into a quantifiable metric in drug discovery, to help find better drugs for mechanical diseases. We screen 100,000s of drugs against numerous contractile human cell types to comprehensively map human mechanobiology (the contractome) and identify promising drug development starting points to deliver novel medicines to treat mechanically-driven diseases including asthma, hypertension, preterm labor, fibrosis, and others.
Federal research funding
11 NIH awards totalling $3,185,607, FY2018 to FY2022.
- Small molecule enhancers of detrusor contraction discovered using a functional cell contractility screen as th
- Smart, integrated well-plates for ultra-high-throughput screening of excitation-contraction coupling in tissue
- Functional high-throughput contractility assay suite to develop therapeutics for asthma andhypertension
Source: NIH RePORTER.
Securities filings
2 Form D filings on record, 2019.
Filed as Forcyte Biotechnologies, Inc.
Source: SEC EDGAR. Form D reports an exempt offering; it does not confirm funds raised.
Company data compiled and maintained by Healthcare Discovery.
